Thymalin

Thymalin (Thymic peptide extract) is a polypeptide fraction. The HEIVE catalog describes it as: A thymus extract from the same Soviet programme as Epithalon; long-term cohort claims are hard to verify.

HEIVE groups Thymalin under immune balance, immune ageing, infection defense, infection recovery and inflammation. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for Thymalin under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. Separately, the Samson-Med label identifies Russian registration LS-000267 for a thymus-extract intramuscular product.

• FDA product data (October 6, 2026)
• Manufacturer Thymalin label

The HEIVE editorial risk summary for Thymalin lists: Injection-site pain; occasional low-grade fever. Longer-term concerns: Unstandardised extract composition. Batch-to-batch variance is the real unknown. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Thymalin has no single onset time established by this catalog. The editorial timeline starts with “Days 1–10”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Thymalin: 10 mg daily for 5–10 days per course. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Thymalin as having limited evidence. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists only injectable forms for Thymalin; it does not establish that every studied or marketed form is injectable.

Preparation of Thymalin depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Thymalin depends on the specific formulation (injectable in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Thymalin: Cycled 10 days, twice yearly, by convention. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Thymalin and Thymosin α-1 share the catalog categories immune balance, infection recovery and infection defense. Thymalin: A thymus extract from the same Soviet programme as Epithalon; long-term cohort claims are hard to verify. Thymosin α-1: Thymosin alpha-1 is listed in FDA compounding safety information. Country-specific registrations are not verified here. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Thymosin α-1

The HEIVE editorial summary highlights: Long-term cohort reports claim mortality differences that no independent group has reproduced. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.